Mirum Pharmaceuticals, Inc.
NASDAQ: MIRM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christopher Peetz
- Employees
- 334
- Headquarters
- Foster City, United States
- IPO year
- 2019
- Market cap
- $5.4B
- Website
- https://www.mirumpharma.com
Loading MIRM…
Loading profile data…Frequently asked questions about MIRM
What does Mirum Pharmaceuticals, Inc. (MIRM) do?
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atre...
Where does MIRM trade?
Mirum Pharmaceuticals, Inc. (MIRM) trades on the NASDAQ Global Market.
What sector is MIRM in?
Mirum Pharmaceuticals, Inc. (MIRM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Mirum Pharmaceuticals, Inc.?
Christopher Peetz is the chief executive officer of Mirum Pharmaceuticals, Inc. (MIRM).
Where is Mirum Pharmaceuticals, Inc. headquartered?
Mirum Pharmaceuticals, Inc. is headquartered in United States.
Does MIRM pay a dividend?
Mirum Pharmaceuticals, Inc. (MIRM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MIRM go public?
Mirum Pharmaceuticals, Inc. (MIRM) completed its initial public offering in 2019.